POLYTRIM
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYTRIM is an ophthalmic antibiotic solution approved in 1988 for bacterial eye infections. It is a fixed-dose combination small molecule indicated for topical ocular use. The product treats common bacterial conjunctivitis and related eye conditions.
$0.938MPart D
LOE ApproachingDeclining
Product is in declining phase with minimal Part D utilization, indicating small commercial team and limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POLYTRIM offers limited career growth opportunities given its LOE-approaching status, minimal Part D spending ($938K), and zero linked job openings. Roles on this product involve defensive commercial strategies and legacy brand management rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on POLYTRIM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.